In recent years, multiple probiotics have been tested in randomized controlled trials for IBS (Irritable Bowel Syndrome), but due to differences in strain tested and methodology, making recommendations concerning which probiotics are beneficial for the management of IBS has been difficult to date.
A new well-conducted meta-analysis by renowned gastroenterology experts has been published in the most prominent journal for the field: Gastroenterology, the official journal of the American Gastroenterological Association.
In this study, the authors assessed three endpoints in IBS populations: global symptoms—abdominal pain—bloating, or distension.
Discover the key facts on the study and how S. cerevisiae CNCM I-3856 is now acknowledged as one of the most documented probiotic strains for IBS symptom management, specifically for abdominal pain.
Latest news & videos
- News
- Quatrefolic®
- Wellness & Immune
- Jun 12, 2025
Webinar Rethinking Women’s Health 24 June 2025
Women's health is complex, constantly evolving, and a broader perspective is long overdue, one...
- News
- Quatrefolic®
- Wellness & Immune
- Jun 09, 2025
Gnosis by Lesaffre Highlights Quatrefolic® at New Nutrition Forum in Hangzhou, China
Gnosis by Lesaffre was proud to serve as the Title Sponsor of the New...
- Corporate
- Digestion & Gut
- News
- Jun 06, 2025
Biotic Live: A Successful First Edition Exploring the Power of Probiotic Yeasts
Gnosis by Lesaffre recently hosted the first edition of Biotic Live, a unique event...
